CurveBeam AI

Q1 FY26 QUARTERLY COMPANY CALL

30 October 2025

HiRise™

FY26 Q1 KEY ACTIVITIES

- **Purchase orders (POs) for four (4) devices in Q1 FY26**, three (3) of which were HiRise™ – growth of **33.3% over the prior corresponding period.**

- **Placement completed to raise A$6.5m** from institutional & sophisticated investors.

- **Increased engagement from the vendor** of a major robotic system for the validation of the enhanced HiRise™. CurveBeam AI has conducted several meetings including a system demonstration with the vendor R&D team during Q1FY26.

- **China Strategy** – the company has executed final contracts with Weiying Intelligent Medical Technology (WIMT), a JV with Wego Orthopedics. The deal grants WIMT exclusive right to **(1) Chinese distribution of CVB US products,** initially based on transfer price; and **(2) to manufacture locally** and sell CVB's WBCT products in China based on a royalty from sales. WIMT will also make investments – all at **$0.405 per share –** with **A$4m** upfront and a further **A$6m** to be invested subject to commercial & regulatory milestones.

- **Vendor Financing Facility** – the company advanced efforts to establish a vendor financing facility and signed an agreement with an international financing partner for a facility of **approximately A$18 million** (€10 million).

- **Maintains target of mid-CY26 for FDA clearance of the bone mineral density (BMD)** Multiple Detector CT (MDCT) software module.

CurveBeam AI

CHINA STRATEGY

CHINA MARKET OPPORTUNITY

- ✓ 38,000 hospitals in China
- ✓ Public hospitals account for less than one-third
- ✓ Public hospitals accounted for 83.5 percent of the total number of patient visits nationwide

TARGETED STRATEGIC BENEFITS

- ✓ Capital injection with reduced dilution – A$10m at 40.5 cents
- ✓ Rapid entry into one of the world's largest & fastest-growing medical device markets
- ✓ China will be initially supplied US manufactured HiRise – short term boost to company sales
- ✓ Commercial validation & expanded global footprint – CVB is commercially validated as a global technology leader in WBCT & AI imaging

CHINA MANUFACTURING

- ✓ Once China manufactured device is MNPA approved – business changes to royalty payments
- ✓ Volume-based manufacturing should deliver lower costs & greater margins (outside US)
- ✓ Accelerated innovation – enables more cost effective & faster design, development, & commercialisation of next-generation imaging devices
- ✓ Meets the requirement of Volume Based Procurement (VBP) in the Chinese state system
- ✓ Dual-factory strategy (China & US) reduces supply chain risk
- ✓ Reduces US-tariff related risks and allows options to manage
- ✓ Opens up global market access to markets CVB can't presently access due to costs

Note: Re-approval from China FDA will be required for the China Manufactured HiRise system

Source - https://english.www.gov.cn/english.www.gov.cn/news/202411/30/content_WS674a493ac6d0868f4e8ed8a9.html

CHINA AGREEMENTS

	Key terms
Share Subscription Agreement & Voluntary Escrow Deed	• The Partner will make an equity investment of up to A$10 million in CVB as follows: • Execution of license agreements A$4 million milestone payment. • HiRise™ sold generating ~A$4.6 million in sales – A$1 million milestone payment. • HiRise™ sold generating ~A$23 million in sales – A$2 million milestone payment. • Regulatory (NMPA) & next generation product release milestones totalling A$3 million. • The shares will be issued at $0.405. If all milestones are met, total shares are expected to be approximately 5% of CVB's current issued share capital. • Escrow Provisions – Each tranche of shares issued will be held subject to voluntary escrow for 24 months in accordance with market-standard terms, to align the Partner's interests with the long-term success of the collaboration.
Common Provisions Across All Agreements	• Non-compete – Partner agrees not to manufacture or distribute competing products, without the prior consent of CVB. • Ten Year Term – IP Licence, Manufacturing & Distribution Agreements operate for an initial term of ten (10) years. • Governing law & dispute resolution – The Licence Agreements are governed by the laws of Singapore. The Share Subscription and Escrow Deed are governed by the laws of Australia. • Arbitration – Disputes are to be referred to mediation followed by arbitration in Singapore.

CurveBeam AI

CHINA AGREEMENTS

	Key terms
Intellectual Property Collaboration & Licence Agreement ("IP Licence Agreement")	• IP Licence Agreement – granting Partner the right to utilise CVB's proprietary WBCT & AI technology & related know-how for the Term in the Territories. • Regulatory Approval – CVB is responsible for seeking, obtaining & maintaining regulatory approval in the Territories for the US manufactured products subject to the Distribution Agreement, & the Partner is responsible for such matters for the Chinese manufactured products subject to the Manufacturing Licence Agreement. • Joint Steering Committee (JSC) – collaboration overseen by JSC, to be established by CVB & the Partner, with equal representation.
Manufacturing Licence Agreement	• Exclusive License for Partner to manufacture CVB's products within the Territories for the Term. Allows the Partner to manufacture the products exclusively for sale in the Territories, and supply CVB with products for sale in markets outside the Territories. • CVB will continue to manufacture products in the US to serve global markets. • Royalties – China manufactured Products: Partner will pay market standard royalties cascading based on sales volumes to be applied as credits for products purchased.
Distribution Agreement	• US product – The Partner has been appointed as CVB's exclusive distributor for the Territories for the Term, with responsibilities for marketing and sales of CVB's product portfolio. • Minimum sales targets (MST) – The MST will be agreed upon annually, on a product-by-product basis. • Delivery – The products are supplied Ex-Works (currently, the US).

CurveBeam AI

Discontinued

Q1 FY26 PURCHASE ORDERS ANALYSIS



	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1
Rest of world	1	3	6	11	2	4	7	10	0
United States	2	4	6	11	1	9	13	16	4

- During Q1 FY26 CurveBeam AI received POs for three HiRise™ devices, and one InReach™ device. This is **a growth of 33.3% over the prior corresponding period** of three purchase orders in Q1 FY25. All device sales were in the USA.
- **Cash at the end of FY26 Q1 was A$2.2m**, with receivables plus cash due from previous POs of a further A$5.1m. In addition, the company has received proceeds of A$6.5m from the completed placement and will receive this quarter A$4m from the Chinese deal

CurveBeam AI

ENHANCED HIRISE™ PROJECT FOR ROBOTIC AIDED SURGICAL SYSTEMS



- The Company is pleased with the increased engagement from the vendor of a major robotic system for validation of the enhanced HiRise™. CurveBeam AI has conducted several meetings including a system demonstration with the vendor R&D team during Q1FY26, demonstrating the latest scanning procedure & the new upgraded patient movement-mitigation mechanism.
- The Company continues to remain confident that its document and data submissions meet the requirements to complete validation and corresponding labelling changes.
- It should be noted that the process is an internal one to the vendor's organisation, subject to its judgment and priorities, and makes it difficult for the Company to provide guidance on completion target at this point.
- Meetings were held last week (AAHKS conference) with executives of the vendor around ways of moving forward the file within the vendor system.

CurveBeam AI

BMD SAAS MDCT MODULE UPDATE

Multidetector CT (MDCT)



HiRise

- Revised BMD regulatory strategy – clear the first BMD module on multidetector CT (MDCT) scanners, the primary technology used today.
- This strategic shift enables earlier access to modest SaaS revenues from existing acute-care trauma settings, an initial application for rapid BMD results from MDCT scans in the U.S. market.
- The file remains on a 510(k) class II pathway – additional comparison with BMD obtained from Dual energy X-ray (DXA) requested by FDA.
- All additional clinical data has been collated and processed in September 25.
- The file has been held up to ensure the required data management platform is verified and validated as part of the original filing (not serial). The DMP is a key component to offer an automated BMD as a SaaS based MDCT product.
- The file submission to the FDA is for November 2025. The Company remains on a target for FDA clearance in H1 CY26.
- A Special 510K is targeted to file post this first MDCT FDA clearance to deliver an FDA cleared BMD SaaS for the HiRise™.

CurveBeam AI

WBCT COMPETITORS – UPDATE

PlanMed Verity
- Available today – FDA, CE, TGA
- Partial foot, Ankle, knee
- Unilateral and not natural bilateral weight bearing
- Difficult for elderly to access – must pull full weight onto affected joint
- To do the knee, contralateral limb approaches a perpendicular position

Large MDCT scanner – not suited for group surgeon settings

Canon Aquilion RISE

SinoVision

PlanMed XFI – WBCT – in development/future competition
- US FDA clearance announced
- Space & height limits access in group surgeon settings
- No automated multiple Dx bone fragility solution – CVB IP protected

CurveBeam AI

DEFINITIONS



CurveBeam AI's key metrics are defined and interpreted as follows:

- **Purchase order** – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time.
- **Receipts from customers** – any cash consideration received from a customer by CurveBeam AI. This can include initial deposits required at the time of an order being placed.
- **Revenue** – Revenue is recognised after the device (e.g., HiRise™) is delivered, installed and training has been completed. Depending on the customer site requirements, there can be several months' delay from a signed purchase order to recognition of revenue. Thus, revenue may not be reflective of sales progress in each period.

The Company will report on POs and cash receipts in its Appendix 4C (quarterly) lodgments, while revenue will be reported in Appendix 4E (full year report) and Appendix 4D (half year report).